Diatrizoate Sodium

CHEMBL1200581 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
635.9 g/mol
LogP
Phase
4

A sodium salt of the iodinated contrast agent diatrizoate, used in radiological imaging procedures such as urography, venography, and CT scans to make blood vessels, organs, and body cavities visible on X-ray images. The iodine atoms absorb X-rays, creating contrast between structures. It can cause allergic reactions and kidney damage, particularly in patients with existing kidney problems.

Molekularmasse

635,8900 g/mol

TPSA

98,30 Ų

Therapeutische Bereiche

Wirkmechanismus

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)[O-])c1I.[Na+]

InChI

InChI=1S/C11H9I3N2O4.Na/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18;/h1-2H3,(H,15,17)(H,16,18)(H,19,20);/q;+1/p-1

Molecular Formula

C11H8I3N2NaO4

HBD / HBA

2 / 4

Rotierbare Bindungen

3

Schwere Atome

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A sodium salt of the iodinated contrast agent diatrizoate, used in radiological imaging procedures such as urography, venography, and CT scans to make blood vessels, organs, and body cavities visible on X-ray images. The iodine atoms absorb X-rays, creating contrast between structures. It can cause allergic reactions and kidney damage, particularly in patients with existing kidney problems.

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Yes, Diatrizoate Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200581. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23672589. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.